CrossrefInfokarte
A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors
Cancer Chemotherapy and Pharmacology · 2025-12 · 95 (1)
DOI: 10.1007/s00280-025-04760-1 ↗Abstract
Kein Abstract verfügbar.
EUVIMED